Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.


Research Abstracts: Conference 2006

Abstracts were presented at the 7th International PH Conference and Scientific Sessions held in Minneapolis, MN, June 23-25, 2006.

  1. Delivery of Intravenous Treprostinil at Low Infusion Rates Using a Miniaturized Infusion Pump in Patients with Pulmonary Arterial Hypertension
  2. “Unexplained” Pulmonary Hypertension and Normal Ejection Fraction in Elderly Patients: Idiopathic Pulmonary Arterial Hypertension or Diastolic Heart Failure?
  3. Calcium Channel Blockers Impair Right Atrial Contractility and Cardiac Output in Non- Responders with Chronic Pulmonary Hypertension
  4. BMPR2 Mutations Are Not Found In Portopulmonary Hypertension Patients
  5. Rapid switch from Intravenous Epoprostenol to Intravenous Treprostinil in patients with pulmonary arterial hypertension
  6. Long-term follow-up and survival of BMPR2 mutation positive vs. negative patients
  7. Diagnostic Criteria for Idiopathic Pulmonary Arterial Hypertension (IPAH) Do Not Reflect Patients Treated for IPAH at a Referral Pulmonary Hypertension (PH) Clinic
  8. Correction of rheological properties of blood in severe chronic obstructive pulmonary disease patients with pulmonary hypertension
  9. A Single-Nucleotide Polymorphism (-254 C to G) in the TRPC6 Gene is Associated with Idiopathic Pulmonary Arterial Hypertension
  10. Short-Term Mortality in Patients After Single or Bilateral Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension: Analysis of the UNOS Database
  11. Long-Term Safety Profile of Bosentan in Patients With Systemic Sclerosis and Pulmonary Arterial Hypertension: Results From the TRAX Database
  12. No Clinical Interaction between Sitaxsentan and Sildenafil
  13. Ambrisentan Improves Exercise Capacity and Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension: Results of the ARIES-2 Study
  14. Do Liver Function Abnormalities With Bosentan Recur With Sitaxsentan?
  15. BREATHE-5: Bosentan improves hemodynamics and exercise capacity in the first randomized placebo-controlled trial in Eisenmenger physiology
  16. Combination of Bosentan with Prostanoids or Sildenafil in Pulmonary Arterial Hypertension was Well Tolerated: Results from the TRAX Database
  17. Hemodynamic Comparisons Between Transthoracic Doppler Echocardiography and Right Heart Catheterization in Patients with Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis
  18. Preparatory clinical study on treatment of pulmonary arterial hypertension associated with connective tissue diseases with sildenafil: experience from a Chinese academic hospital
  19. Long-Term Benefits of Sildenafil Treatment on Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension
  20. Dramatic Pulmonary Vascular Changes in a Liver Transplant Candidate
  21. Vasoreactivity Tests and TGF-B type II Receptor Gene Mutations
  22. Changes in a V Wave during a Nitric Oxide Vasodilator Trial for Pulmonary Hypertension:  Unmasking Left Heart Disease
  23. Single Center Experience with Rapid Dose Escalation of Sub-Cutaneous (SQ) Treprostinil for the Treatment of Pulmonary Arterial Hypertension
  24. Hemodynamic response during six-minute walk tests and during daily living in patients with pulmonary arterial hypertension
  25. Ambulatory right ventricular and pulmonary artery pressure response to treatment with bosentan and treprostinil in patients with pulmonary arterial hypertension
  26. Comparison Of Sitaxentan And Bosentan In Pulmonary Arterial Hypertension Associated With Connective Tissue Diseases
  27. Relation Between Pulmonary Arterial Pressure Response and Exercise Tolerance in Pulmonary Arterial Hypertension Patients Treated with Bosentan or Treprostinil
  28. Brain Natriuretic Peptide Levels in Patients With PAH Attending the 2004 Miami PHA Meeting: Relationship to Diuretic Requirement and WHO Class
  29. Severe Chronic Pulmonary Hypertension Sheep Model By Continuous Intravenous Air Infusion Induced Pulmonary Air Embolism
  30. Sildenafil Improves Exercise Ability and Hemodynamics in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
  31. Estimation Of Cardiac Index In Patients With Pulmonary Hypertension: Thermal Dilution Vs. Fick’s Method
  32. PRX-08066: A Potent 5-HT2B Receptor Antagonist with a dual disease modifying/vasodilating mechanism for the Treatment of Pulmonary Hypertension
  33. Right Index of Myocardial Performance (RIMP) as a Predictor of Death or Lung/Heart Transplantation in Patients with Pulmonary Hypertension (PH)
  34. Left Atrial Volume as an Indicator of Left Heart Disease in Patients with Pulmonary Hypertension
  35. Efficacy of Sildenafil Treatment and Improved Survival After 1 Year in Patients With Pulmonary Arterial Hypertension (PAH)
  36. Registry to EValuate Early And Long-term PAH Disease Management (REVEAL Registry™ )
  37. Etiology specific reductions in pulmonary endothelial angiotensin converting enzyme activity in patients with PAH and Chronic Thromboembolic PH
  38. One Year Experience with Intravenous Treprostinil in Pulmonary Arterial Hypertension (PAH) Patients
  39. Quercetin Represses NADPH oxidase subunit p22phox Gene Expression: A Molecular Mechanism to Control ROS-Linked Functions and Dysfunction
  40. Acute Vasoreactivity and Genetic Polymorphisms in IPAH/FPAH Children and Adults
  41. Pulmonary Hypertension In Children With Sickle Cell Disease
  42. Combination Therapy with Sildenafil and Bosentan and Epoprostenol Weaning in Patients with Pulmonary Arterial Hypertension
  43. The effects of eNOS deficiency on pulmonary vascular remodeling in pulmonary hypertension
  44. Effect of Prostacyclins on Thrombocytopenia in Portopulmonary Hypertension
  45. Right Heart Catheterization is Necessary to Confirm and Further Characterize Portopulmonary Hypertension
  46. The Plasma Proteome in Pediatric Idiopathic Pulmonary Arterial Hypertension: A Compelling Case for Angiogenesis in Patients who Respond to Vasodilator Therapy
  47. Endothelin-1 Up-regulates Plasminogen Activators and Plasminogen Activator Inhibitor- type1 Gene Expression in Cultured Human Pulmonary Endothelial Cells
  48. Human Analogue BNP in the Management of Right Heart Failure due to Secondary Pulmonary Hypertension
  49. Ultrafiltration: A Safe and Effective Treatment for Right Ventricular Failure due to Pulmonary Hypertension
  50. Successful Liver Transplantation Following Medical Management of Portopulmonary Hypertension; a Single Center Series
  51. B-type natriuretic peptide (BNP) response to six-minute walk test (6MWT) in Pulmonary Arterial Hypertension (PAH)
  52. Pulmonary vascular adaptations in swine with secondary pulmonary hypertension after myocardial infarction- role of endothelin
  53. rhVEGF Treatment Preserves Pulmonary Vascular Reactivity and Structure in an Experimental Model of Pulmonary Hypertension in Fetal Sheep
  54. Cognitive Impairment is Common in Patients with Pulmonary Arterial Hypertension
  55. Simvastatin Potently Suppresses Rho-Kinase in Chronic Hypoxic Pulmonary Hypertension
  56. Elevated plasma endothelin-1 (ET1) levels are associated with death in newborns with congenital diaphragmatic hernia (CDH)
  57. A Novel Gas Exchange Assist Device in Juvenile Porcine Acute Lung Injury
  58. Role of integrins in hypoxic pulmonary hypertension: expression and mobilization of intracellular Ca2+ in rat pulmonary arterial smooth muscle cells (PASMCs)
  59. Thrombospondin-1 in Hypoxic Pulmonary Vascular Remodeling
  60. The bone morphogenetic protein type II receptor regulates bone morphogenetic protein signaling and function in pulmonary vascular smooth muscle cells


  Sign in to add a review